Real-World Effectiveness and Safety of Anti-CGRP Monoclonal Antibodies in the Prevention of High-Frequency Episodic and Chronic Migraine in Romania-A Multicenter Retrospective Observational Study
Abstract
Background: Real-world evidence regarding the effectiveness and safety of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies in Eastern European populations remains limited. We aimed to evaluate treatment outcomes and safety in Romanian patients with high-frequency episodic migraine (HFEM) and chronic migraine (CM). Methods: We conducted a multicenter retrospective observational cohort study including 113 adults with HFEM (n = 38) or CM (n = 75) who initiated treatment with galcanezumab, erenumab, fremanezumab, or eptinezumab at specialized headache centers in Romania. Monthly migraine days (MMDs) in HFEM and monthly headache days (MHDs) in CM were assessed at the baseline and during follow-up. Treatment outcomes, discontinuation, persistence, and adverse events were evaluated during routine clinical follow-up. Results: At month 6, headache frequency was substantially reduced in both groups, with median MMDs decreasing from 10 to 2 in patients with HFEM and median MHDs decreasing from 25 to 6 in patients with CM. A ≥50% reduction in headache frequency was achieved by 78.9% of patients with HFEM and 64.0% of those with CM. Among the patients with CM, 70.7% met the predefined criterion for conversion to episodic migraine at month 6. During follow-up, 22 patients discontinued treatment. Adverse events were reported in 28 patients (24.8%), were predominantly non-serious, and resulted in treatment discontinuation in 3 patients (2.7%). No serious adverse events were…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 113 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.